Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:22:22.714Z.
Calculation as of: 2026-10-06T17:22:22.714Z.
Quote observation: 2026-10-06T17:20:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fa669979e2b3f995ef920df13c3a539cab2f3704a4556e475e3dd75e53b0e3a2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Kestra Medical Technologies, Ltd.
Market Cap
$1.60B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.62B
EV/EBITDA Ratio
6.72x
TTM Avg
10.54x
3Y Avg
14.62x
5Y Avg
19.17x
Market Cap
$1.64B
EV/EBITDA Ratio
57.12x
TTM Avg
223.11x
3Y Avg
223.11x
5Y Avg
223.11x
Market Cap
$1.54B
EV/EBITDA Ratio
N/A
TTM Avg
399.33x
3Y Avg
399.33x
5Y Avg
399.33x
Market Cap
$1.53B
EV/EBITDA Ratio
4.34x
TTM Avg
3.71x
3Y Avg
17.44x
5Y Avg
17.91x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kestra Medical Technologies, Ltd. (KMTS) | $1.60B | N/A | N/A | N/A | N/A |
| Omnicell, Inc. (OMCL)vs › | $1.59B | 10.62x | 16.19x | 22.90x | 28.26x |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | N/A | N/A | N/A | N/A |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 6.72x | 10.54x | 14.62x | 19.17x |
| Septerna Inc (SEPN)vs › | $1.63B | N/A | N/A | N/A | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.64B | 57.12x | 223.11x | 223.11x | 223.11x |
| Innoviva, Inc. (INVA)vs › | $1.54B | 4.93x | 69.99x | 32.98x | 22.10x |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | N/A | 399.33x | 399.33x | 399.33x |
| Nutex Health, Inc. (NUTX)vs › | $1.53B | 4.34x | 3.71x | 17.44x | 17.91x |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.53B | N/A | 37.36x | 37.36x | 37.36x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
